Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | CCR8 | P51685 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179292 | 0.83 | TRPV1 (0.37) | LMNANFE2L2ALDH1A1KDM4ETDP1 | |
| SCHEMBL27748876 | 0.80 | NFE2L2 (0.34) | LMNANFE2L2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL18668145 | 0.79 | HSD11B1 (0.39) | LMNANFE2L2SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL29724855 | 0.79 | DPP4 (0.36) | LMNANFE2L2SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL369947 | 0.79 | TRPV1 (0.35) | NFE2L2TDP1TRPV1 | |
| SCHEMBL3866262 | 0.79 | JAK2 (0.33) | LMNANFE2L2ALDH1A1GAATRPV1 | |
| SCHEMBL30592740 | 0.78 | TDP1 (0.39) | LMNANFE2L2SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL3257764 | 0.78 | TDP1 (0.39) | LMNANFE2L2SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL1332434 | 0.77 | NOS3 (0.45) | LMNASMN1; SMN2KDM4EKMT2ACCR1 | |
| SCHEMBL20609516 | 0.76 | TDP1 (0.40) | LMNANFE2L2SMN1; SMN2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281885-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (US) | 2011-11-17 | — | — | US | disclosed |
| US-7799786-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2010-09-21 | — | — | US | disclosed |
| EP-1810970-B1 | Therapeutic piperazine compounds | EURO CELTIQUE SA (LU) | 2010-05-12 | — | — | EP | disclosed |
| US-20080153835-A1 | Therapeutic agents useful for treating pain | EURO-CELTIQUE S.A. | 2008-06-26 | — | — | US | disclosed |
| EP-1556354-B1 | THERAPEUTIC PIPERAZINE DERIVATES USEFUL FOR TREATING PAIN | EURO CELTIQUE SA (LU) | 2008-01-23 | — | — | EP | disclosed |
| US-7279493-B2 | cyanoiminopiperazines which inhibit vanilloid receptor 1 function in a cell | EURO-CELTIQUE S.A. | 2007-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153835-A1 | Therapeutic agents useful for treating pain | CHRM2, CHRM1, MC1R | LMNA 2309/4885NFE2L2 3363/4885SMN1; SMN2 59/4885 |
| US-20110281885-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | CHRM2, CHRM1, MC1R | LMNA 2309/4885NFE2L2 3363/4885SMN1; SMN2 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.